Original language | Undefined/Unknown |
---|---|
Pages (from-to) | E195-E204 |
Journal | LANCET HIV |
Volume | 4 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2017 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. / Orkin, C; DeJesus, E; Ramgopal, M; Crofoot, G; Ruane, P; LaMarca, A; Mills, A; Vandercam, B; de Wet, J; Rockstroh, J; Lazzarin, A; Rijnders, Bart; Podzamczer, D; Thalme, A; Stoeckle, M; Porter, D; Liu, HC; Cheng, A; Quirk, E; SenGupta, D; Cao, H.
In: LANCET HIV, Vol. 4, No. 5, 2017, p. E195-E204.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
AU - Orkin, C
AU - DeJesus, E
AU - Ramgopal, M
AU - Crofoot, G
AU - Ruane, P
AU - LaMarca, A
AU - Mills, A
AU - Vandercam, B
AU - de Wet, J
AU - Rockstroh, J
AU - Lazzarin, A
AU - Rijnders, Bart
AU - Podzamczer, D
AU - Thalme, A
AU - Stoeckle, M
AU - Porter, D
AU - Liu, HC
AU - Cheng, A
AU - Quirk, E
AU - SenGupta, D
AU - Cao, H
PY - 2017
Y1 - 2017
U2 - 10.1016/s2352-3018(17)30031-0
DO - 10.1016/s2352-3018(17)30031-0
M3 - Article
VL - 4
SP - E195-E204
IS - 5
ER -